Dr. Lal Path Labs Ltd. — Investor Meet, 05-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs kicked off FY26 strong with Q1 revenue up 11.3% to Rs. 670 Cr, PAT surging 24.3% to Rs. 134 Cr, and EBITDA up 13.1% to Rs. 192 Cr. Volume growth (samples up 10.7%) and favorable test mix, especially from SwasthFit (27% of revenue), boosted results without price hikes. Management confirmed a stable 28.7% EBITDA margin, possibly better for the full year. They're expanding network, launching high-complexity tests, and investing in digital transformation. Despite competitive shifts and Mumbai/Pune integration challenges, the outlook remains confident on volume-led growth and strategic expansion in Tier-2/3/4 towns.